In this regard, we have previously reported that I/D and D/D genotypes and higher (> 135 ng/mL) levels of circulating ACE were associated with better responses to bevacizumab treatment at any time point of the disease in metastatic breast cancer or CRC patients [22]. The gene discussed is ACE; the disease is colorectal carcinoma.